REG - Hikma Pharmaceutical - Director/PDMR Shareholding
04/03/2025 11:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250304:nRSD3056Za&default-theme=true
RNS Number : 3056Z Hikma Pharmaceuticals Plc 04 March 2025
Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 4 March 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons
Discharging Managerial Responsibility ("PDMR") have received shares as a
result of the vesting or exercise of their conditional share awards which were
granted on 25 February 2022 under the 2014 Executive Incentive Plan ("EIP")
Element C and on 17 March 2016 under the EIP Element B.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element
C.
All Shares were retained.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 18,420
d) Aggregated information Price(s): nil
Volume(s): 18,420
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element C
and exercise of conditional awards under the EIP Element B.
All Shares were retained.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil EIP Award, Element C: 18,691
Nil EIP Award, Element B: 19,890
d) Aggregated information Price(s): nil
Volume(s): 38,581
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element
C.
All Shares were retained.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 14,844
d) Aggregated information Price(s): nil
Volume(s): 14,844
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element
C.
All Shares were retained.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 17,003
d) Aggregated information Price(s): nil
Volume(s): 17,003
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Bassam Kanaan
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element
C.
All Shares were retained.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 16,472
d) Aggregated information Price(s): nil
Volume(s): 16,472
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Susan Ringdal
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element
C.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 8,851
d) Aggregated information Price(s): nil
Volume(s): 8,851
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares sold to cover tax following the vesting of conditional awards under the
EIP Element C.
c) Price(s) and volume(s) Price(s) Volume(s)
£21.71 4,173
d) Aggregated information Price(s): £21.71
Volume(s): 4,173
Total(s): £90,596.87
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards under the EIP Element
C.
All Shares were retained.
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 8,675
d) Aggregated information Price(s): nil
Volume(s): 8,675
e) Date of the transaction 28 February 2025
f) Place of the transaction London Stock Exchange (XLON)
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
4 March 2025
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBBGDXSBGDGUSRecent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement